Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Contract MRs to Increase from 1,500 to 2,600 Next Year: Quintiles Seminar
July 9, 2001
- Daiichi to Apply for Prevention of Recurrent Stroke for Coversyl
July 9, 2001
- Yutaka Pharmacy Acquires Local Drugstores in Aichi
July 9, 2001
- Determination of Anti-acid-fast Bacteria Antibody Covered by Insurance
July 9, 2001
- REGULATORY NEWS IN BRIEF -2-
July 9, 2001
- 4,310 ADRs Reported by Monitor Pharmacies in Tokyo in 10 Years
July 9, 2001
- REGULATORY NEWS IN BRIEF -1-
July 9, 2001
- Japanese Makers' Globalization Discussed: Interphex Japan
July 9, 2001
- Safety Info. No. 267 Focuses on Reye Syndrome Due to Salicylate
July 9, 2001
- Yamanouchi Forms Alliance with Celera Genomics
July 9, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 9, 2001
- JPMA to Propose New Drug Benefit System: Mr Nagayama
July 9, 2001
- Non-member Countries' Interest in ICH to Be Surveyed
July 9, 2001
- Sysmex: POC Test Information System
July 9, 2001
- JMA Proposes New Medical Fee Payment System by Type of Medical Institution
July 9, 2001
- Tanabe to License DDS Technology to aaiPharma in the US
July 9, 2001
- Council Recommends that Profit-making Companies Operate Hospitals
July 9, 2001
- Medrad to Directly Market Image Diagnostic Systems
July 9, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
July 9, 2001
- JEOL: EIA-based Radical Analyzer
July 9, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…